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California, San Francisco, CA, USAA B S T R A C TObjectives: To determine the cost-effectiveness of tyrosine kinase
inhibitors erlotinib or afatinib, or chemotherapy cisplatin-peme-
trexed, for ﬁrst-line treatment of advanced epithelial growth factor
receptor mutation-positive non–small-cell lung cancer in the United
States. We also assessed the expected beneﬁt of further research to
reduce uncertainty regarding which treatment is optimal. Methods:
We developed a Markov model to compare the cost-effectiveness of
erlotinib, afatinib, and cisplatin-pemetrexed. Model transition and
adverse-effect probabilities were from two published phase III trials:
EURTAC (Erlotinib versus standard chemotherapy as ﬁrst-line treat-
ment for European patients with advanced EGFR mutation-positive
non-small-cell lung cancer) and LUX-Lung (Afatinib versus cisplatin-
based chemotherapy for EGFR mutation-positive lung adenocarci-
noma) 3. EURTAC survival estimates were corrected for patients
entering the trial with more severe disease, compared with LUX-
Lung 3. Health utilities and costs were from national estimates or the
published literature. Inputs were modeled as distributions for proba-
bilistic sensitivity analysis and expected value of perfect information
(EVPI) analysis to estimate the expected beneﬁt of reducing
uncertainty regarding the decision of optimal treatment. Results: Inee front matter Copyright & 2015, International S
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.1016/j.jval.2015.04.008
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cisco, CA 94143.the base case, both tyrosine kinase inhibitors were more cost-effective
than cisplatin-pemetrexed. Erlotinib had an incremental cost-
effectiveness ratio of $61,809/quality-adjusted life-year (QALY) com-
pared with afatinib. The acceptability curve showed that erlotinib
was the optimal treatment at a willingness-to-pay threshold of
$100,000/QALY (10-year population EVPI ¼ $85.9 million). At
a willingness-to-pay threshold of $50,000/QALY to $70,000/QALY
(EVPI ¼ $211.5 million–$261.8 million), however, there was consider-
able uncertainty whether erlotinib or afatinib was the optimal treat-
ment. Conclusions: Our analysis suggests that erlotinib is the
preferred ﬁrst-line treatment for advanced epithelial growth factor
receptor mutation-positive non–small-cell lung cancer. Further
research comparing erlotinib and afatinib is potentially justiﬁed,
although accurate data are needed on the required cost and sample
size of the trial.
Keywords: cost-effectiveness, EGFR mutation-positive NSCLC, expected
value of perfect information, treatment, value-of-information.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Lung cancer is the most common cancer worldwide, accounting
for approximately 13% of all cancers and approximately 19% of
cancer-related deaths in 2012 [1]. A total of 85% to 90% of all lung
cancers are non–small-cell lung cancer (NSCLC) [2], with approx-
imately 80% of NSCLC cases in advanced stage (stage IIIB/IV) at
diagnosis [3]. In patients with NSCLC, epidermal growth factor
receptor (EGFR) mutations, found in 10% to 15% of Western
patients and up to 50% of Asian patients, play an important role
in tumor development and progression [4–6]. Currently, the
National Comprehensive Cancer Network recommends EGFR-
tyrosine kinase inhibitors (TKIs) for ﬁrst-line treatment of
advanced EGFR mutation-positive NSCLC [7]. Phase IIIrandomized clinical trials (RCTs) showed signiﬁcant superiority
of TKIs over standard chemotherapy in prolonging progression-
free survival (PFS) in treatment-naive patients with advanced
EGFR mutation-positive NSCLC [8].
In 2013, the US Food and Drug Administration approved oral
TKIs erlotinib (Tarceva®, Genentech Inc., California, USA) and
afatinib (Gilotrif®, Boehringer Ingelheim GmbH, Ingelheim,
Germany) for ﬁrst-line treatment of advanced EGFR mutation-
positive NSCLC in the United States. Each treatment’s phase III
efﬁcacy data suggest that erlotinib and afatinib may have
similar PFS [9,10], although patients on afatinib appeared to
experience more severe diarrhea and rash. Without a head-to-
head trial, it is uncertain whether one treatment provides true
incremental value over the other in terms of efﬁcacy, toxicity,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 7 4 – 7 8 2 775and cost. Also, compared with chemotherapy, which is given for
six cycles (21 days per cycle), the total drug cost of TKIs may be
considerably higher, especially if patients do well on the treat-
ment, because patients on TKIs are treated until disease pro-
gression or lack of tolerability.
For decision makers, the choice between TKIs or chemo-
therapy ultimately depends on their comparative costs and
effectiveness. To our knowledge, only two economic analyses
have evaluated erlotinib for ﬁrst-line treatment of advanced EGFR
mutation-positive NSCLC, both conducted in Asian populations
[11,12]. Cost-effectiveness of afatinib has not been evaluated. We
used simulation modeling to compare the cost-effectiveness of
these three treatments for ﬁrst-line treatment of advanced EGFR
mutation-positive NSCLC for the United States. Because the cost-
effectiveness analysis may show uncertainty regarding the deci-
sion of optimal treatment, we also estimated the expected value
of perfect information (EVPI) to estimate the expected beneﬁt of
further research (and whether it is justiﬁed) to reduce this
decision uncertainty [13,14].Methods
Study Population
We used data from two published phase III RCTs of patients with
advanced (stage IIIB/IV, TNM Classiﬁcation of Malignant Tumours,
6th edition) EGFR mutation-positive NSCLC undergoing ﬁrst-line
treatment with erlotinib [15], afatinib, or cisplatin-pemetrexed
[16]. Because we aimed for our results to be generalizable to the
US patient population, we used data from the phase III RCT that
included Western patient populations. The erlotinib versus
cisplatin-carboplatin or gemcitabine RCT (EURTAC) had a median
follow-up of 18.9 months, and the afatinib versus cisplatin-
pemetrexed RCT (LUX-Lung 3) 16.4 months. The median age of
patients was as follows: erlotinib arm, 61.5 years; afatinib arm,
65.0 years; and cisplatin-pemetrexed arm, 61.0 years. A total of
14% of the participants in EURTAC had Eastern Cooperative
Oncology Group (ECOG) score 2, whereas the remaining had an
ECOG score of 0 or 1. All participants in LUX-Lung 3 had an
ECOG score of 0 or 1. We chose cisplatin-pemetrexed as our0.0
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Fig. 1 – Progression-free survival (PFS) curves for erlotinib (EURTAC
ﬁrst-line treatment of advanced EGFR mutation-positive NSCLC. T
expectancy method was used to extrapolate the PFS from 32 to 36
3 [16]. EGFR, epidermal growth factor receptor; NSCLC, non–small-control because it is currently listed as a category 1 recommen-
dation in the National Cancer Care Network guidelines for
NSCLC [17].
Markov Model
We developed a Markov model using TreeAge Pro 2014 (TreeAge
Software, Williamstown, MA) (Fig. 1) to estimate the cost-
effectiveness of erlotinib, afatinib, and cisplatin-pemetrexed for
patients with ﬁrst-line treatment of advanced EGFR mutation-
positive NSCLC. We also determined the EVPI to estimate the
expected beneﬁt of further research to reduce uncertainties
regarding the decision of optimal treatment.
Our model had three branches at the decision node, each
representing one of the three treatments being compared. All
patients started in stage IIIB/IV NSCLC (Fig. 1A). Cycle lengths
were 1 month, and time horizon was lifetime. In each simulation
cycle, patients remained stable in stage IIIB/IV disease, pro-
gressed from stage IIIB/IV disease, or died. After progression,
patients could stay in the progressed state or die. We simulated
the progression of disease until all patients entered the death
state (terminal state). Primary model outcomes were cost and
effectiveness of the three treatments, expressed in quality-
adjusted life-year (QALY). We compared the cost and effective-
ness of any two treatments using incremental cost-effectiveness
ratio (ICER): (CostDrug1 – CostDrug2)/(QALYDrug1 – QALYDrug2). Treat-
ments were ranked by cost from lowest to highest. We used a US
societal approach. To be considered cost-effective, a treatment
must have an ICER of less than $100,000/QALY compared with an
alternative, consistent with the US societal preference [18].
Model Inputs
Inputs in our Markov model were 1) monthly transition proba-
bilities for PFS, disease progression, and death; 2) probability of
adverse effects under each treatment; 3) health state utilities, for
quality adjustment of transition and adverse-effect probabilities
(expressed by QALY weights); and 4) costs. Erlotinib monthly PFS
and overall survival (OS) probabilities were from EURTAC. Afati-
nib and cisplatin-pemetrexed PFS data were from LUX-Lung 3,
and the OS data were from the Food and Drug Administration
statistical evaluation report on afatinib because ﬁnal OS results18 21 24 27 30 33 36
 (months)
Afatinib
Erlotinib (corrected)
Erlotinib (uncorrected)
Cisplatin-pemetrexed
[15]), afatinib (LUX-Lung 3 [16]), and cisplatin-pemetrexed for
he declining exponential approximation for calculating life
months in EURTAC [15] and from 24 to 36 months in LUX-Lung
cell lung cancer. (Color version of ﬁgure is available online.)
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We used the declining exponential approximation for calculating
life expectancy method to extrapolate the PFS and OS curves
beyond the follow-up duration of the trials [20] (Fig. 1).
For our base-case analysis, survival estimates under erlotinib
were corrected for ECOG patients entering the trial with an ECOG
score of more than 1. We estimated the weighted hazard ratio
(HR) across patients with an ECOG score of 0 to 2 (HR012), as well
as across patients with an ECOG score of 0 to 1 (HR01), on the basis
of ECOG score–speciﬁc HRs published in EURTAC [15]. We then
divided HR012 by HR01 to obtain the relative difference in survival
between those with an ECOG score of more than 1 and those with
an ECOG score of 0 to 1. We then multiplied the monthly survival
probabilities for erlotinib by 1.064 (HR012/HR01) to obtain the
corrected survival estimates.
We obtained adverse-effect probabilities for each treatment
from EURTAC and LUX-Lung 3 (Table 1). We included grade 3 or 4
adverse effects, which occurred in more than 5% of the patients,
and grade 1 or 2 adverse effects, which occurred in more than
50% of the patients, because these may be regarded as an
important risk of drug treatment. Utility estimates for each
health state (stage IIIB/IV disease, progressed disease, and death)
with and without adverse effects were obtained from previous
cost-effectiveness studies on patients with NSCLC on a TKI
versus chemotherapy.
Drug utilization rates were from EURTAC and LUX-Lung 3.
Monthly drug costs were from RED BOOK Online 2013 (Truven
Health Analytics, New York, NY) and discounted at 17% to
account for contract pricing, consistent with estimates of reim-
bursement by Medicare and other third-party payers (Table 1).
Medical services and drug administration costs were from the
Centers for Medicare & Medicaid Services base rate in 2013. All
costs were adjusted to 2013 US dollars using the Consumer Price
Index for medical care services and discounted at 3% annually,
consistent with current practice. Data on managing adverse
effects including health care utilization and associated costs
were from the literature.
Probabilistic Sensitivity Analysis
We performed Monte-Carlo simulation (N ¼ 10,000 iterations) to
simultaneously account for uncertainty in all model parameters
(Table 1), including transition probabilities at each cycle. We
assigned beta distributions to probability and utility estimates and
gamma distribution to cost estimates. In each iteration, this method
randomly drew a value from the distributions in Table 1. For each
treatment option, we estimated the lifetime costs and effectiveness
(expressed as QALY), as well as the uncertainty around these
estimates, expressed as 95% conﬁdence intervals (CIs) [21].
We constructed a cost-effectiveness acceptability curve to
estimate the joint impact of parameter uncertainty and poten-
tial variability in the decision maker’s willingness-to-pay (WTP)
threshold for considering a treatment cost-effective. This
method uses the net beneﬁt (NB) framework, deﬁned as follows:
NB¼EffectivenessWillingness to pay – Cost
At any given WTP threshold, the optimal treatment is the one
with the highest NB. An acceptability curve shows the proportion of
model iterations in which a treatment had the highest NB (y-axis)
at a given WTP threshold (x-axis), that is, the probability that the
true ICER is equal to or less than the WTP threshold (Fig. 2) [22,23].
Value-of-Information Analysis
Our decision questions were to determine the optimal treatment
choice among erlotinib, afatinib, and cisplatin-pemetrexed, and
further, the choice between the two TKIs, for ﬁrst-line treatment
of patients with advanced EGFR mutation-positive NSCLC. Theoptimal treatment can be expressed as the one with the highest
expected NB (NBC). However, uncertainty around costs and
QALYs means that our choice of optimal treatment may be
“incorrect.”
Using probabilistic sensitivity analysis, we may analyze the
results in each of the N ¼ 10,000 iterations and choose the
treatment with the highest NB in each iteration. The expected
NB is the mean of the maximum NB across all iterations (i.e., the
expected value of a decision made on the basis of perfect
information about our parameters [NBP]). The EVPI is NBP – NBC.
Further research to decrease parameter uncertainty is justiﬁed if
the cost of research is less than the EVPI. We calculated the EVPI
per patient and for the US patient population (population EVPI).
We compared the population EVPI against a range of WTP
thresholds for an effective lifetime of treatments of 1 (2013), 5
(2013–2017), and 10 years (2013–2022) (Fig. 3). Future beneﬁts were
discounted annually at 3%.
We estimated the partial EVPI for individual or combinations
of input parameters to identify parameters with the highest
expected informational value. These are the parameters for
which more data should be collected in a future study. We used
a two-level Monte-Carlo sampling loop, in which a parameter of
interest was sampled M ¼ 500 times in the outer loop, and for
every iteration M, the remaining parameters were sampled N ¼
10,000 times in the inner loop. We multiplied the per-patient
partial EVPI by our effective patient population to obtain the
population’s partial EVPI over 1, 5, and 10 years.
Model Validation
Figure 1 shows the curves of corrected and uncorrected PFS from
EURTAC, as well as the curves of the PFS from LUX-Lung 3. In our
base-case analysis, the risk of progression under afatinib was
similar to that under erlotinib (estimated HR using PFS at 12
months ¼ 0.96; 95% CI 0.61–1.30), but appeared somewhat lower
when compared with that under uncorrected erlotinib (HR ¼ 0.84;
95% CI 0.53–1.16). Neither association was statistically signiﬁcant.
In a network meta-analysis of ﬁrst-line studies [24], the HR for the
PFS of afatinib versus erlotinib was 0.86 (95% CI 0.50–1.50), some-
what similar to our HR estimate using the uncorrected model, but
nevertheless also not statistically signiﬁcant. It is worth noting
that that our HR estimates were calculated using a single point
estimate (PFS at 12 months). Thus, although our base-case HR
showed similar efﬁcacy between afatinib and erlotinib, the PFS in
the corrected erlotinib curve was higher than that in the afatinib
curve at times 0 to 9 months and more than 18 months, whereas
in the uncorrected erlotinib curve, the PFS of erlotinib was higher
than that of afatinib only at times more than 18 months.Results
Cost-Effectiveness Analysis
In the base case, afatinib had the lowest cost, followed by cisplatin-
pemetrexed and then erlotinib (Table 2A). The total lifetime cost of
the erlotinib treatment arm was more than that of the afatinib
treatment arm owing to improved effectiveness under erlotinib,
resulting in longer PFS and treatment time. Erlotinib was the most
effective, followed by afatinib and then cisplatin-pemetrexed.
Differences in effectiveness were statistically signiﬁcant across
all three treatments, but differences in costs were not. Both TKIs
were more cost-effective than cisplatin-pemetrexed. Given a
choice between the TKIs, erlotinib was cost-effective compared
with afatinib, with a mean ICER of $61,809/QALY.
The acceptability curve (Fig. 2A) shows that afatinib was the
optimal treatment below a WTP threshold of $30,000/QALY. With
Table 1 – Model input parameters, distribution, and range.
Parameter Base case Range Distribution Source
Low High
Treatment cost ($)
Erlotinib (150-mg tablet, monthly cost) 5751* 4313 7189 Gamma RED BOOK, 25%
Afatinib (40-mg tablet, monthly cost) 5550* 4162 6937 Gamma RED BOOK, 25%
Cisplatin (127.5-mg per cycle)† 5302‡ 3976 6627 Gamma RED BOOK, 25%
pemetrexed (850-mg per cycle)†
Cost of managing adverse events ($)§
Diarrhea (inpatient) 8589 6442 10,736 Gamma [33], 25%
Diarrhea (outpatient) 188ǁ 141 235 Gamma RED BOOK, 25%
Rash 7872 543 16,288 Gamma [34]
Stomatitis/mucositis 10,366¶ 9265 11,467 Gamma [33]
Fatigue (inpatient) 10,967 10,213 11,721 Gamma [33]
Fatigue (outpatient) 244# 185 205 Gamma RED BOOK, 25%
Neutropenia (inpatient and follow-up care) 32,995 24,746 41,244 Gamma [35], 25%
Neutropenia (outpatient) 8589 6442 10,736 Gamma [33], 25%
Nausea 2586** 1939 3232 Gamma RED BOOK, 25%
Cost of disease progression 13,537 11,056 15,949 Gamma [36]
Risk of adverse events under erlotinib (%)
Diarrhea (grade 3/4) 5 0 17 Beta [15,37]
Diarrhea (grade 1/2) 47 32 66 Beta [15,37]
Rash (grade 3/4) 13 0 14 Beta [15]
Rash (grade 1/2) 54 49 75 Beta [15,37]
Stomatitis/mucositis (grade 3/4) 0 0 2.7 Beta [15]
Stomatitis/mucositis (grade 1/2) 0 0 23 Beta [15,37]
Fatigue (grade 3/4) 6 0 23 Beta [15]
Fatigue (grade 1/2) 45 20 50 Beta [15,37]
Nausea (grade 1/2) 0 0 16 Beta [15,37]
Neutropenia (grade 1/2) 0 0 10 Beta [15,37]
Risk of adverse events under afatinib (%)
Diarrhea (grade 3/4) 14.4 0 33 Beta [16,37]
Diarrhea (grade 1/2) 80.8 73 83 Beta [16,38]
Rash (grade 3/4) 16.2 0 25 Beta [16,37]
Rash (grade 1/2) 72.9 66 80 Beta [16,38]
Stomatitis/mucositis (grade 3/4) 8.7 6.5 10.9 Beta [16], 25%
Stomatitis/mucositis (grade 1/2) 63.4 47 70 Beta [16,38]
Fatigue (grade 3/4) 1.3 1 1.6 Beta [16], 25%
Fatigue (grade 1/2) 16.2 10 18 Beta [16,38]
Nausea (grade 1/2) 17 8.8 18.7 Beta [16,38]
Neutropenia (grade 3/4) 0.4 0.3 0.5 Beta [16], 25%
Neutropenia (grade 1/2) 0.5 0.4 1.7 Beta [16,38]
Risk of adverse events under cisplatin-pemetrexed (%)
Diarrhea (grade 3/4) 0 0 9 Beta [16]
Diarrhea (grade 1/2) 15.3 11.5 19.1 Beta [16], 25%
Rash (grade 3/4) 0 0 39.4 Beta [16]
Rash (grade 1/2) 6.3 4.7 7.9 Beta [16], 25%
Stomatitis/mucositis (grade 3/4) 0.9 0.8 6 Beta [16]
Stomatitis/mucositis (grade 1/2) 14.4 10.8 18 Beta [16], 25%
Fatigue (grade 3/4) 12.6 0 27 Beta [16]
Fatigue (grade 1/2) 12.6 9.5 15.8 Beta [16], 25%
Nausea (grade 3/4) 3.6 2.7 4.5 Beta [16]
Nausea (grade 1/2) 62.2 46.7 77.8 Beta [16], 25%
Neutropenia (grade 3/4) 18 3 22.5 Beta [16]
Neutropenia (grade 1/2) 13.5 10.1 16.9 Beta [16], 25%
Risk of hospitalization due to grade 3/4 adverse events (%)
Diarrhea 27.5 20.6 34.4 Beta [39], 25%
Fatigue 22 16.5 27.5 Beta [39], 25%
Neutropenia 37.5 28.1 46.9 Beta [40], 25%
Health utilities††
Stable disease under oral therapy 0.67 0.48 0.84 Beta [41], 25%
Stable disease under IV therapy 0.65 0.49 0.81 Beta [41], 25%
Stable disease with neutropenia 0.56 0.42 0.7 Beta [41], 25%
continued on next page
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Table 1 – continued
Parameter Base case Range Distribution Source
Low High
Stable disease with diarrhea 0.61 0.46 0.76 Beta [41], 25%
Stable disease with stomatitis/mucositis 0.61 0.46 0.76 Beta [41], 25%
Stable disease with rash 0.62 0.47 0.78 Beta [41], 25%
Disease progression 0.47 0.35 0.59 Beta [41], 25%
IV, intravenous, NCCN, National Comprehensive Cancer Network; RCT, randomized controlled trial.
* Includes the administration cost of one outpatient ofﬁce visit for initial prescription. All drug prices are average wholesale price minus 17%.
† Dosage for average body surface area of 1.7 m2.
‡ Includes the administration cost of one outpatient ofﬁce visit and 1-h IV infusion time per cycle. Patients were modeled to undergo six cycles
(21 d per cycle) of chemotherapy, according to the median duration of chemotherapy in LUX-Lung 3 [16]. The monthly cost of chemotherapy
was estimated by dividing the total cost of treatment by the approximate number of chemotherapy cycles undergone in 1 mo. Given the
highly emetogenic nature of high-dose cisplatin, we assumed that patients received prophylaxis with fosaprepitant, dexamethasone, and
ondansetron, per the NCCN Antiemesis Guidelines (NCCN Antiemesis Guidelines v.3.2014) [17].
§ Costs are for the median treatment duration in EURTAC [15] and LUX-Lung 3 RCT—8.2 mo for erlotinib, 11.1 mo for afatinib, and 6 mo for
cisplatin-pemetrexed. Cost of managing grade 1/2 adverse events include the cost of one outpatient visit and subsequent recommended
therapy for the median length of treatment seen in the clinical trials. Outpatient neutropenia and fatigue include the cost of one outpatient
medical visit.
ǁ Includes one outpatient visit, loperamide (2 mg/d), diphenyloxylate, and atropine, and one chemistry panel.
¶ Includes one outpatient visit and lidocaine viscous solution (100 ml).
# Includes one outpatient visit.
** Includes one outpatient visit, and metoclopramide (10 mg/d) and lorazepam (1 mg/d).
†† Utilities from the literature were based on standard gamble interview and visual analogue scale.
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optimal treatment increased, whereas that of afatinib and
cisplatin-pemetrexed decreased. Between WTP thresholds of
$50,000/QALY and $70,000/QALY, the probability that erlotinib
or afatinib was the optimal treatment was between 35% and 55%,
indicating considerable uncertainty in the choice of optimal
treatment between erlotinib and afatinib. At a WTP threshold of
$100,000/QALY, only erlotinib and afatinib remained viable treat-
ment options, and erlotinib was preferred over afatinib.
Outcomes Using Uncorrected Erlotinib Survival Probabilities
When EURTAC survival probabilities were not corrected, afatinib
appeared to have similar effectiveness, but was more costly
compared with erlotinib (Table 2B). Erlotinib became the least
expensive, perhaps due to decreased survival and shorter treat-
ment time, and caused less severe adverse effects compared with
afatinib. As in the base-case analysis, both TKIs were more cost-
effective than cisplatin-pemetrexed. Afatinib had an ICER of
$534,903/QALY compared with erlotinib, clearly not cost-
effective. The acceptability curve (Fig. 2B) showed that erlotinib
was the optimal treatment in approximately 90% or more of the
iterations at any given WTP, compared with afatinib and
cisplatin-pemetrexed. Thus, when not accounting for patients
with poorer ECOG scores in the erlotinib trial, erlotinib was also
the preferred treatment in this model.
Value of Information
The total EVPI per person in the base-case analysis was $685 at a
WTP threshold of 100,000/QALY. We obtained the number of new
NSCLC cases in 2013 in the United States from the Surveillance,
Epidemiology, and End Results Program [3]. Assuming that 10% to
15% of the patients with NSCLC in the United States are EGFR
mutation-positive [4,5], and 79% of diagnoses were in the
advanced stage [3], we estimated our patient population in 2013
to be approximately 15,632. The estimated population EVPI in
2013 was thus $10.7 million ($685  15,632) (Fig. 3). Over a 10-yeartime horizon at 1.3% annual decline in lung cancer incidence
observed in the United States over the last decade [3], the value of
information for 141,949 eligible patients was $85.9 million. This
means that at a societal WTP of $100,000/QALY, an RCT compar-
ing the efﬁcacy of erlotinib with afatinib in patients with
advanced NSCLC harboring EGFR mutations would be of beneﬁt
to society if the cost of the trial is less than $85.9 million. A
shorter effective lifetime for the treatment from 10 to 5 years will
reduce these beneﬁts by approximately half (Fig. 3). The peak in
the curve observed at a WTP threshold of approximately $60,000/
QALY, corresponding to an EVPI of $261.8 million, indicates that
the expected beneﬁt of further research to reduce decision
uncertainty is highest at this WTP threshold. This corresponds
to the region in the acceptability curve of our base-case analysis
(Fig. 2A) between WTP thresholds of $50,000/QALY and $70,000/
QALY (Fig. 2A), where there was considerable uncertainty regard-
ing the choice between erlotnib and afatinib for optimal
treatment.
The following parameters had nonzero partial EVPIs at a WTP
threshold of $100,000/QALY: monthly drug cost of erlotinib ($484)
and monthly drug cost of afatinib ($92). Probability and cost of
rash together under afatinib had a nonzero partial EVPI at WTP
thresholds of $70,000 or less/QALY and ranged from $4.1 to
$214.3. This means that at a WTP threshold of $100,000/QALY,
monthly drug cost of erlotinib and that of afatinib accounted for
most (480%) of the decision uncertainty.Discussion
In the base-case analysis, we found that erlotinib was cost-
effective compared with afatinib and cisplatin-pemetrexed at a
WTP threshold of $100,000/QALY. The acceptability curve showed
that uncertainty regarding decision of erlotinib versus afatinib
was highest at a WTP threshold of $50,000/QALY to $70,000/
QALY, but showed a greater amount of certainty that erlotinib
was the preferred treatment at a WTP threshold of $100,000/
QALY. Population EVPI analysis showed that the estimated
Fig. 2 – Acceptability curve for erlotinib, afatinib, and cisplatin-pemetrexed for ﬁrst-line treatment of advanced EGFR mutation-
positive NSCLC. (A) Base-case analysis. Monthly survival estimates in EURTAC (erlotinib trial) [15] were corrected for
participants with poorer ECOG performance status compared with those in LUX-Lung 3 (afatanib trial) [16]. (B) Without
correction of the monthly survival estimates in EURTAC. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth
factor receptor; NSCLC, non–small cell lung cancer; QALY, quality-adjusted life-year. (Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 7 4 – 7 8 2 779expected beneﬁt of conducting further research is $85.9 million,
assuming an effective lifetime of 10 years for current treatments
at 3% discount annually. This means that at a WTP threshold of
$100,000/QALY, a future RCT to determine the optimal choicebetween erlotinib and afatinib would be justiﬁed given a trial size
of fewer than 860 patients at approximately $100,000 per trial
patient, consistent with the average per-person cost in a phase III
RCT of cancer treatment in 2013 [25,26].
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Fig. 3 – The expected value for further information for US patient population aged 60 years or older undergoing ﬁrst-line
treatment for advanced EGFR mutation-positive NSCLC. EGFR, epidermal growth factor receptor; EVPI, expected value of
perfect information; NSCLC, non–small cell lung; QALY, quality-adjusted life-year. (Color version of ﬁgure is available online.)
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 7 4 – 7 8 2780Based on currently available data, erlotinib is the preferred
treatment in only 75% to 80% of model iterations at a WTP
threshold of $100,000/QALY (Fig. 2A), suggesting that there is still
uncertainty as to whether choosing erlotinib over afatinib is
always justiﬁed. Given the estimated population EVPI ($85.9
million), is a further RCT a worthwhile use of resources? To our
knowledge, there is currently no estimate in the literature on the
cost of a phase III trial speciﬁc for advanced NSCLC. The
estimated average cost of a phase III cancer RCT in 2013 was
$41.7 million [25,26], making a further RCT to compare erlotinib
and afatinib for ﬁrst-line treatment justiﬁable because the cost of
the trial is less than the estimated expected beneﬁt. The costs of
cancer drug trials, however, can be very variable—the cost of a
phase III cancer RCT in 2013 could be as high as $88.0 million
[25,26], whereas another study reported a mean cost of $86.3
million in 2000 US dollars [27], exceeding our estimated
expected beneﬁt. Also, because erlotinib and afatinib have
similar efﬁcacy, a larger sample size than either EURTAC (N ¼
117) or LUX-Lung 3 (N ¼ 345) may be required for adequate
power to detect clinically signiﬁcant differences between the
two treatments. Assuming per-patient cost of a phase III cancer
RCT of $75,000 to $125,000 in 2013 [25,26], a further RCT could be
justiﬁed if the required trial size is between 687 and 1145 ($85.6
million divided by per-person cost). Sample size calculation
should thus be undertaken to help decide whether a further
RCT is justiﬁed.
Results of our population EVPI analysis should also be con-
sidered in the overall context of national research prioritization
by comparing the expected societal beneﬁt of $85.9 million with
that of other proposed clinical research; for example, EVPI ¼ $214
million for further research to use breast tumor markers to
monitor disease recurrence [28] and EVPI ¼ $1 billion for research
on optimal management strategy of malignant colorectal polyps
[29]. In this case, although further research regarding treatment
of advanced EGFR mutation-positive NSCLC is potentially justi-
ﬁed, the research on breast cancer recurrence monitoring and
colorectal cancer management should perhaps be assigned a
higher priority.Given the potentially similar efﬁcacy between erlotinib and
afatinib in the ﬁrst-line setting, the choice between them may
depend mostly on differences in drug and adverse-effect costs.
Because of its more severe adverse-effect proﬁle [15,16,30], the
cost of managing adverse effects due to afatinib was the highest
($4609), compared with erlotinib ($2442) and cisplatin-
pemetrexed ($3924). One strategy to make afatinib more cost-
effective is to reduce its cost. Decreasing afatinib’s monthly drug
cost by 21%, from $5648 to $4451, made afatinib as cost-effective
as erlotinib. Afatinib, however, may have better long-term efﬁ-
cacy in cases associated with acquired resistance to ﬁrst-
generation TKIs, including erlotinib [31,32]. Future economic
analyses should consider accounting for this advantage of afati-
nib over ﬁrst-generation TKIs.
Our ﬁnding to prefer erlotinib over afatinib was consistent
with that of a network meta-analysis of ﬁrst-line studies by Liang
et al. [30], where erlotinib was the likeliest among all TKIs,
including afatinib, to be the best treatment in terms of 1-year
PFS (61% vs. 29%). The network meta-analysis of ﬁrst-line studies
by Popat et al. [24] found, however, that afatinib was likeliest to
be the best treatment among other TKIs, including erlotinib (70%
vs. 27%), in terms of PFS. Differences in results from the two
published studies were due to methodological differences, and
potentially studies included in analysis, as well as analysis end
points. It is worth noting, however, that the HR or odds ratio for
afatinib versus erlotinib in terms of PFS in both studies did not
reach statistical signiﬁcance. Also, although results in the pub-
lished studies were driven purely by efﬁcacy data, our study also
accounted for the difference in baseline patient population
between EURTAC and LUX-Lung 3, and the risks of adverse
events and their associated utilities.
This study has several limitations. First, the declining expo-
nential approximation for calculating life expectancy method
used to extrapolate long-term survival beyond the follow-up
duration of the RCTs may not accurately reﬂect the true survival.
This is a good model, however, given the short follow-up
duration in the RCTs and rapid mortality. Second, by correcting
EURTAC survival estimates for participants with an ECOG score of
Table 2 – Cost-effectiveness of afatinib, erlotinib, and cisplatin-pemetrexed as ﬁrst-line treatment of advanced
EGFR mutation-positive NSCLC.
A. Base-case analysis
Treatment Cost ($)
(95% CI)
Effectiveness
(95% CI)
Incremental
cost ($)
(95% CI)
Incremental
effectiveness
(95% CI)
ICER ($)
Comparing all treatments
Afatinib 40,250 0.33 QALYs – – –
(34,215–47,077) (0.32–0.35)
Cisplatin-
pemetrexed
40,555 0.28 QALYs Dominated Dominated Dominated
(31,584–45,781) (0.19–0.32)
Erlotinib 46,972 0.44 QALYs 6,722 0.11 QALYs 61,809/QALY
(38,477–56,563) (0.42–0.46) (–3,732 to 17,635) (0.09–0.13)
Erlotinib vs. cisplatin-pemetrexed
Cisplatin-
pemetrexed
40,555 0.28 QALYs – – –
(31,584–45,781) (0.19–0.32)
Erlotinib 46,972 0.44 QALYs 6,417 0.17 QALY 40,106/QALY
(38,477–56,563) (0.42–0.46) (–3,678 to 18,733) (0.12–0.25)
B. Without correction
Treatment Cost ($)
(95% CI)
Effectiveness
(95% CI)
Incremental
cost ($) (95% CI)
Incremental
effectiveness
(95% CI)
ICER ($)
Erlotinib 32,755 0.32 QALYs – – –
(26,764–39,454) (0.30–0.33)
Afatinib 40,250 0.33 QALYs 7,494 0.014 QALYs 534,903/QALY
(34,215–47,077) (0.32–0.35) (–1,308 to 16,146) (–0.01 to 0.04)
Cisplatin-
pemetrexed
40,555 (31,584–45,781) 0.28 QALYs
(0.19–0.32)
Dominated Dominated Dominated
CI, conﬁdence interval; EGFR, epidermal growth factor receptor; ICER, incremental cost-effectiveness ratio; ECOG, Eastern Cooperative
Oncology Group; NSCLC, non—small-cell lung cancer; QALYs, quality-adjusted life-years.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 7 4 – 7 8 2 781more than 1, we assumed that disease severity is the only effect
modiﬁer in our analysis. In EURTAC, efﬁcacy of erlotinib appeared
to differ signiﬁcantly among those who never smoked and
current smokers, although this difference was not observed with
afatinib in LUX-Lung 3. Without patient-level data, we could not
account for patient heterogeneity across the RCTs. Nevertheless,
efﬁcacy of erlotinib or afatinib did not appear to differ signiﬁ-
cantly among other clinical characteristics in the RCTs’ subgroup
analyses. Third, LUX-Lung 3 is, to date, the only RCT evaluating
afatinib to include Western patients; although 72% of its partic-
ipants were from Asia, we chose this trial for our comparison
because of the concern expressed by the Food and Drug Admin-
istration to have trial results that included Western patients. In
addition, the risk of progression between Asian and non-Asian
patients on afatinib versus those on chemotherapy in LUX-Lung 3
did not differ signiﬁcantly by race, strengthening the conclusion
that this trial’s results and our results were generalizable to the
US population.
To our knowledge, this is the ﬁrst study to evaluate the cost-
effectiveness of erlotinib, afatinib, and cisplatin-pemetrexed for
ﬁrst-line treatment in patients with advanced EGFR mutation-
positive NSCLC, as well as the EVPI of further research. Based on
currently available data, erlotinib appears the preferred ﬁrst-line
treatment for advanced EGFR mutation-positive NSCLC, given a
WTP of more than $50,000/QALY. Because of its more costly
adverse-effect management, afatinib may need to earn its share
in the ﬁrst-line market space with more competitive pricing.Based on a WTP threshold of $100,000/QALY, a further RCT
comparing erlotinib and afatinib for ﬁrst-line treatment of
advanced EGFR mutation-positive NSCLC is potentially justiﬁed,
although more accurate data are needed on the required cost and
sample size of conducting the RCT. Because erlotinib’s monthly
drug cost, afatinib’s monthly drug cost, and the probability and
cost of rash together for afatinib were responsible for most of the
decision uncertainty, better data on these parameters should be
collected in a future trial.
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